Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.29 USD
0.00 (1.19%)
Updated Jul 3, 2024 11:36 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
GLMD 0.29 0.00(1.19%)
Will GLMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GLMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GLMD
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
GLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Other News for GLMD
GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024
Why KKR Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Galmed Pharmaceuticals Calls for Shareholder Votes
Galmed Pharma Reports Q1 2024 Financials
Earnings week ahead: Salesforce, Costco, Canopy Growth, Dell, Dollar General, and more